Chilton Investment Co. LLC increased its holdings in shares of Haemonetics Co. (NYSE:HAE) by 26.1% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 217,825 shares of the medical instruments supplier’s stock after acquiring an additional 45,081 shares during the period. Chilton Investment Co. LLC’s holdings in Haemonetics were worth $12,651,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. Meeder Asset Management Inc. lifted its position in shares of Haemonetics by 2,845.3% during the 4th quarter. Meeder Asset Management Inc. now owns 1,885 shares of the medical instruments supplier’s stock valued at $110,000 after buying an additional 1,821 shares in the last quarter. CIBC Asset Management Inc purchased a new position in shares of Haemonetics during the 4th quarter valued at approximately $210,000. Everence Capital Management Inc. purchased a new position in Haemonetics in the 4th quarter valued at $212,000. Dean Capital Investments Management LLC purchased a new position in Haemonetics in the 4th quarter valued at $246,000. Finally, Shelton Capital Management purchased a new position in Haemonetics in the 2nd quarter valued at $204,000.
In other news, Director Mark W. Kroll sold 7,118 shares of Haemonetics stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $63.00, for a total transaction of $448,434.00. Following the transaction, the director now owns 33,881 shares in the company, valued at approximately $2,134,503. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Dan Goldstein sold 4,691 shares of Haemonetics stock in a transaction on Monday, November 13th. The stock was sold at an average price of $54.93, for a total value of $257,676.63. Following the transaction, the chief accounting officer now owns 3,747 shares in the company, valued at approximately $205,822.71. The disclosure for this sale can be found here. In the last quarter, insiders have sold 37,560 shares of company stock worth $2,133,607. Insiders own 1.20% of the company’s stock.
Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.18. Haemonetics had a positive return on equity of 12.39% and a negative net margin of 1.94%. The company had revenue of $234.04 million for the quarter, compared to analyst estimates of $227.79 million. During the same quarter last year, the firm posted $0.43 EPS. The firm’s revenue for the quarter was up 2.7% on a year-over-year basis. equities research analysts forecast that Haemonetics Co. will post 1.87 earnings per share for the current fiscal year.
Haemonetics declared that its board has approved a stock repurchase program on Tuesday, February 6th that authorizes the company to buyback $260.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its shares are undervalued.
A number of research analysts have weighed in on HAE shares. Zacks Investment Research upgraded Haemonetics from a “hold” rating to a “buy” rating and set a $52.00 price objective on the stock in a report on Wednesday, October 25th. Barrington Research raised their price objective on Haemonetics from $48.00 to $57.00 and gave the company an “outperform” rating in a report on Wednesday, November 8th. Craig Hallum restated a “hold” rating and issued a $50.00 price objective (up previously from $40.00) on shares of Haemonetics in a report on Wednesday, November 8th. Morgan Stanley raised their price objective on Haemonetics from $43.00 to $51.00 and gave the company an “equal weight” rating in a report on Thursday, November 9th. Finally, Raymond James Financial upgraded Haemonetics from an “underperform” rating to a “market perform” rating in a report on Tuesday, January 2nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. Haemonetics currently has a consensus rating of “Hold” and a consensus price target of $70.00.
TRADEMARK VIOLATION NOTICE: This story was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://sportsperspectives.com/2018/02/09/haemonetics-co-hae-stake-lifted-by-chilton-investment-co-llc.html.
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.